Small Molecule Drug Discovery and Development
GE Healthcare offers a broad range of products spanning the drug discovery workflow, that give deeper insights and better understanding of drug compound behavior including: Biacore (surface plasmon resonance) and MicroCal (microcalorimetry) label-free protein interaction analysis systems for confident compound selection and characterization in applications from secondary screening to lead optimization. This is supported by solutions for cell-based analyses such as IN Cell Analyzer systems for high content cell imaging, stem cell-derived cell models for safety screening, and our Cell Factory custom bulk cell production service.
The development of new therapies is often based around the synthesis of small organic compounds to inhibit disease-associated molecular interactions. Once a validated drug target is established, assays are developed to screen up to 100 000 compounds per day. Potential inhibitors, or ”hits”, must then be re-tested and validated using biochemical, biophysical, and cell-based assays.
During the hit-to-lead process, lead compounds are identified and lead series developed and optimized via structural modifications in conjunction with assays providing structure-activity relationship (SAR) data, mode of action information, toxicity indications, and other data useful for predicting efficacy and safety. Once a final candidate is filed as an IND (Investigational New Drug), it is taken into the drug development process where more regulated efficacy and safety studies are performed and clinical trials are undertaken to achieve regulatory approval and commercial marketing.
After selecting a promising drug candidate, studies are performed to investigate efficacy and safety of the drug candidate.
Get deeper insights into drug:target interactions and their functional outcomes, helping you through the entire hit to lead process, from screening through to lead optimization
GE Healthcare provides products for high content screening and structure-based drug design, reducing the incidence of false positives.